173 related articles for article (PubMed ID: 37958997)
1. Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors.
Dolivet E; Gaichies L; Jeanne C; Bazille C; Briand M; Vernon M; Giffard F; Leprêtre F; Poulain L; Denoyelle C; Vigneron N; Fauvet R
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958997
[TBL] [Abstract][Full Text] [Related]
2. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
Saied EM; El-Etreby NM
Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of intraoperative frozen section for the evaluation of ovarian neoplasms: an institutional experience.
Hashmi AA; Naz S; Edhi MM; Faridi N; Hussain SD; Mumtaz S; Khan M
World J Surg Oncol; 2016 Mar; 14():91. PubMed ID: 27029917
[TBL] [Abstract][Full Text] [Related]
5. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
[TBL] [Abstract][Full Text] [Related]
7. Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population.
Nasioudis D; Alevizakos M; Holcomb K; Witkin SS
Maturitas; 2017 Feb; 96():45-50. PubMed ID: 28041594
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic carcinoma in ovarian seromucinous cystic tumor of borderline malignancy.
Okumura T; Muronosono E; Tsubuku M; Terao Y; Takeda S; Maruyama M
J Ovarian Res; 2018 Sep; 11(1):77. PubMed ID: 30176911
[TBL] [Abstract][Full Text] [Related]
9. Fascin and EMMPRIN expression in primary mucinous tumors of ovary: a tissue microarray study.
Alici O; Kefeli M; Yildiz L; Baris S; Karagoz F; Kandemir B
Pathol Res Pract; 2014 Dec; 210(12):934-8. PubMed ID: 25155376
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas.
Hui P; Gysler SM; Uduman M; Togun TA; Prado DE; Brambs CE; Nallur S; Schwartz PE; Rutherford TJ; Santin AD; Weidhaas JB; Ratner ES
Hum Pathol; 2018 Jun; 76():133-140. PubMed ID: 29518404
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas.
Riopel MA; Ronnett BM; Kurman RJ
Am J Surg Pathol; 1999 Jun; 23(6):617-35. PubMed ID: 10366144
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype.
Rattanapan Y; Korkiatsakul V; Kongruang A; Siriboonpiputtana T; Rerkamnuaychoke B; Chareonsirisuthigul T
Microrna; 2020; 9(4):289-294. PubMed ID: 32703147
[TBL] [Abstract][Full Text] [Related]
13. Podocalyxin-like protein 1 expression and correlation with clinical characteristics in epithelial serous and mucinous ovarian carcinoma and tumor-like lesions.
Ye F; Hu Y; Zhou C; Hu Y; Chen H
Pathobiology; 2012; 79(6):307-13. PubMed ID: 22688257
[TBL] [Abstract][Full Text] [Related]
14. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors.
Smithgall MC; Yemelyanova A; Mathew S; Gogineni S; He B; Zhang T; Robinson BD; Tu JJ
Int J Gynecol Pathol; 2024 Mar; 43(2):134-139. PubMed ID: 37406458
[TBL] [Abstract][Full Text] [Related]
15. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor.
Seckin KD; Karslı MF; Yucel B; Bestel M; Yıldırım D; Canaz E; Akbayır O
Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():60-3. PubMed ID: 26683535
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
Jordan SJ; Green AC; Whiteman DC; Webb PM;
Gynecol Oncol; 2007 Nov; 107(2):223-30. PubMed ID: 17662378
[TBL] [Abstract][Full Text] [Related]
17. Mucinous Ovarian Tumors.
Mills AM; Shanes ED
Surg Pathol Clin; 2019 Jun; 12(2):565-585. PubMed ID: 31097115
[TBL] [Abstract][Full Text] [Related]
18. Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.
Yousif HMA; Mohammed RAA
Curr Probl Cancer; 2019 Aug; 43(4):377-385. PubMed ID: 30446260
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with misdiagnosis of frozen section of mucinous borderline ovarian tumor.
Zhang W; Jia S; Xiang Y; Yang J; Jia C; Leng J
J Int Med Res; 2019 Jan; 47(1):96-104. PubMed ID: 30198356
[TBL] [Abstract][Full Text] [Related]
20. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
